A patient with complete paralysis from a five-year-old spinal cord injury can now produce voluntary movement in his lower limbs and has regained partial sensation, one year after surgeons at Xuanwu Hospital in Beijing implanted him with both an invasive brain-computer interface on the cortex and a temporally programmed spinal cord stimulator below the injury site. The Xuanwu Hospital team disclosed the one-year clinical follow-up on 22 May 2026 through Global Times and several Western medical-engineering outlets. The patient was the world’s first to receive both implants simultaneously when the multi-target combined surgery was performed on 16 May 2025. After staged rehabilitation, his clinical classification has improved from ASIA Grade A (complete spinal cord injury) to ASIA Grade C (incomplete spinal cord injury), a category change that has historically been considered medically irreversible for late-stage complete SCI patients.

The combined system

The implant architecture pairs three technologies in closed-loop coordination. Beinao No.1, an invasive brain-computer interface developed by the China Institute for Brain Research (CIBR) and NeuCyber NeuroTech, sits on the motor cortex and decodes the patient’s movement intentions from neural activity. The system feeds those decoded intentions, in seconds, to a temporally programmed spinal cord stimulation device implanted below the injury site, which activates the surviving spinal cord neurons distal to the injury and triggers muscle contraction in the lower limbs. An external exoskeleton provides the mechanical scaffolding for gait reconstruction.

The three-system architecture is closer to the brain-spine interface approach pioneered by Lausanne-based research groups (Grégoire Courtine and Jocelyne Bloch’s team at EPFL and CHUV) and commercialised by Dutch-Swiss company ONWARD Medical, with one structural difference: the Chinese system uses an invasive cortical BCI (Beinao No.1) rather than the epidural cortical electrocorticography (ECoG) array ONWARD has used in its first ARC-BCI participants. The invasive cortical implant offers higher signal resolution at the cost of higher surgical risk.

The patient and the clinical recovery

The patient had a severe T12-L1 spinal cord injury sustained in an accident five years ago, with complete loss of sensation and motor function in both lower limbs. The pre-surgery clinical classification was ASIA Grade A, the most severe category on the ASIA Impairment Scale, indicating no preserved sensory or motor function in the affected segments. One year after the combined surgery and staged rehabilitation, the patient’s classification has moved to ASIA Grade C, indicating some preserved motor function with more than half of key muscles below the neurological level having a muscle grade less than 3.

The clinical change matters because the long-held neurology consensus has been that ASIA Grade A injuries do not spontaneously convert to lower grades, and that the loss of motor function below the injury level after complete SCI is permanent. A ASIA A to ASIA C conversion through neuroprosthetic intervention rather than natural recovery is a meaningful clinical data point for the broader brain-spine interface category.

How this compares to ONWARD and the broader field

ONWARD Medical reported its first ARC-BCI implants in 2024 with three patients implanted by the start of 2025, with first-in-human data showing voluntary lower-limb movement restoration via a brain-recorded intent-to-stimulator-trigger architecture. ONWARD’s ARC-BCI participants were classified at less severe ASIA levels at baseline than the Xuanwu patient, which makes the Chinese case structurally different. A complete-to-incomplete classification change in a patient five years post-injury with a T12-L1 lesion is a harder clinical demonstration than functional improvement in a patient with preserved partial function at baseline.

The Xuanwu case extends a small but growing global cohort of brain-spine interface patients. ONWARD has reported seven ARC-BCI implants total per its January 2026 disclosure. The Lausanne research group has reported multiple patients via published Nature papers since 2023. The Chinese cohort, anchored on the Beinao No.1 invasive cortical interface, now adds a distinct architectural branch to the same therapeutic indication.

What this signals about China’s BCI clinical infrastructure

The Xuanwu disclosure is the latest in a sequence of Chinese BCI clinical milestones over the past three months, including Beinao-1’s livestreamed surgery on 14 April 2026, China’s NHSA pricing guidance for invasive BCI procedures on 23 April 2026, and Order 818 establishing a parallel commercial pathway for invasive BCI on 8 May 2026. The pattern is consistent: Chinese clinical-stage BCI is moving from single-surgeon demonstrations into multi-site clinical work, reimbursement infrastructure, and commercial regulatory framework simultaneously.

The Xuanwu case differs from those earlier disclosures in being a true clinical-outcome readout rather than a surgical-event announcement or regulatory framework. A one-year ASIA grade improvement is publishable peer-reviewed clinical evidence, not a commercial-pathway milestone. Whether the Xuanwu team publishes the case formally in a peer-reviewed journal (Nature, Lancet, or NEJM are the standard targets for brain-spine interface clinical results) will determine how the case is received by Western neurology audiences.

What to watch

The first signal to watch is whether the Xuanwu case becomes a peer-reviewed publication. Brain-spine interface clinical results have established a publication pattern in Nature and Lancet over the past three years (Lorach et al. 2023 Nature, Wagner et al. 2018 Nature). The second signal is whether the Xuanwu team or NeuCyber NeuroTech expands the procedure to additional patients. A second and third case would convert the May 2025 surgery from “world-first demonstration” into “early clinical cohort,” with implications for the broader Beinao No.1 commercial trajectory. The third signal is the upcoming ONWARD Medical Q1 2026 results on Tuesday 26 May, which will include an updated ARC-BCI implant count and any progression of the Lausanne-Dutch-Swiss programme’s clinical evidence base. The Chinese and ONWARD architectures are now in active comparison.

Sources

• China reports breakthrough in spinal cord injury treatment with brain-spine joint interface system (Global Times, 22 May 2026)
• World-first: Paralyzed patients walk with China’s brain-spinal chip (Interesting Engineering)
• Brain-spine interface restores mobility in paralysed patient (Surgery International)
• China conducts 4th brain-spine interface surgery on paralyzed patients (CGTN, March 2025)
• Walking naturally after spinal cord injury using a brain–spine interface (Lorach et al., Nature, 2023 — for comparator context)